Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity.
about
European guidance for the diagnosis and management of osteoporosis in postmenopausal womenScreening, diagnosis and treatment of osteoporosis: a brief reviewFever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.Pulsed electromagnetic fields improve bone microstructure and strength in ovariectomized rats through a Wnt/Lrp5/β-catenin signaling-associated mechanismModerate-intensity rotating magnetic fields do not affect bone quality and bone remodeling in hindlimb suspended ratsAdverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis.Risedronate's Role in Reducing Hip Fracture in Postmenopausal Women with Established Osteoporosis.Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medicationsStrontium Ranelate: Long-Term Efficacy against Vertebral, Nonvertebral and Hip Fractures in Patients with Postmenopausal Osteoporosis.A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis.Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis.Strontium ranelate: a look back at its use for osteoporosis.Safety of long-term bisphosphonate therapy for the management of osteoporosis.Current options for the management of postmenopausal osteoporosis.Adverse drug reactions to osteoporosis treatments.Models and screening assays for drug discovery in osteoporosis.HLA and pharmacogenetics of drug hypersensitivity.Management of osteoporosis of the oldest old.Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate.Pulsed electromagnetic fields promote in vitro osteoblastogenesis through a Wnt/β-catenin signaling-associated mechanism.Bergamot Polyphenol Fraction Exerts Effects on Bone Biology by Activating ERK 1/2 and Wnt/β-Catenin Pathway and Regulating Bone Biomarkers in Bone Cell Cultures
P2860
Q24612411-EC85B3A0-E837-4928-994B-635316FC3019Q26996726-AC3DF0BE-7194-4224-A63C-E2F5F299EAB4Q27692095-5632402E-13B9-4276-890C-0C28C4BDE3DEQ28302165-51471CB4-25F9-4849-A7CB-F135AAC6AAD5Q28540994-591361A4-9269-4CE6-9811-124A0625C882Q34189582-01665F3A-75E6-4F34-AEB0-F23123883203Q35678676-7DC5F9ED-4629-48A2-8C59-2989A677E091Q35740351-BF9500DC-6378-42D3-9C2E-1B7CF99BE836Q36056938-0DDF6FDF-67B1-4D2D-8152-D6539994CC19Q36999717-ABB9B08E-B00B-4E1D-88D0-ED17F596DC7BQ37780535-64F46F10-5D49-4978-8C9E-072575B1CB0AQ37807038-14597BA6-95B5-45DC-B400-228729151DCCQ37866764-70B68D02-1E7E-4472-8B8E-2A6534F5760CQ37931985-DF421465-54BE-42D3-AAA6-81A3289987DBQ37973355-70B98844-653F-475F-BC64-71A924B1C507Q38028513-9A0E9A86-7540-4878-97D5-B0159EAFCBECQ38037649-770971D5-F1BA-40C9-8132-C6871FCC3C37Q38229503-2DEFC0EA-41ED-4817-9B0D-21D4018C17B2Q51178470-4C8BC523-28B5-462C-BBED-8EA9E70A4861Q51513277-E4B009CF-406A-4B0F-9BD2-63C071679C53Q58738994-91974FA9-A4BB-41C2-9446-3B2EDC85DAEA
P2860
Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Treatment of osteoporosis: rec ...... drug-induced hypersensitivity.
@en
Treatment of osteoporosis: rec ...... drug-induced hypersensitivity.
@nl
type
label
Treatment of osteoporosis: rec ...... drug-induced hypersensitivity.
@en
Treatment of osteoporosis: rec ...... drug-induced hypersensitivity.
@nl
prefLabel
Treatment of osteoporosis: rec ...... drug-induced hypersensitivity.
@en
Treatment of osteoporosis: rec ...... drug-induced hypersensitivity.
@nl
P2093
P1476
Treatment of osteoporosis: rec ...... drug-induced hypersensitivity.
@en
P2093
J M Kaufman
J-Y Reginster
M L Brandi
P2888
P304
P356
10.1007/S00198-009-1097-5
P407
P577
2009-11-17T00:00:00Z